Back

Serial changes of 99mTc- pyrophosphate uptake in patients with hereditary transthyretin amyloid cardiomyopathy treated with tafamidis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Heart failure: bench to bedside Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor An-Li Yu

National Taiwan University Hospital Hsin-Chu Branch, Hsinchu (Taiwan)

9 More presentations in this session

Presentation thumbnail
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
Doctor P. Gouda (Edmonton, CA)
Abstract Slides Video
Presentation thumbnail
A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.
Miss B. Goovaerts (Antwerp, BE)
Abstract Slides Video
Presentation thumbnail
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
Professor J. Udelson (Boston, US)
Abstract Slides Video
Presentation thumbnail
Unmasking patients insight into SGLT2 inhibitors- a collaborative quality improvement project to enhance patient education and safety
Doctor L. Saad (Coventry, GB)
Abstract Slides Video
Presentation thumbnail
Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model
Doctor M. Kowala (Zionsville, US)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: bench to bedside

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis
thumbnail
Congress Presentation
Plasma transthyretin fractions in transthyretin cardiac amyloidosis patients undergoing tafamidis treatment
thumbnail
Congress Presentation
12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources